Dr Reddy's Laboratories has entered into a licensing pact with Japan's Eisai Co. Ltd for “exclusive worldwide development and commercialisation rights (excluding Japan and Asia)” for the latter's investigational anticancer agent E7777. In exchange, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets, Dr Reddy's said.